Rhythm Pharmaceuticals Reports 67% Revenue Growth to $48.5 Million, Net Loss of $46.6 Million for Q2 2025

Rhythm Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated $48.5 million in product revenue for the second quarter, marking a 67% increase from $29.1 million in the same period last year. For the first half of 2025, total revenues reached $81.2 million, up 48% from $55.0 million in the first half of 2024. Despite this revenue growth, the company reported a net loss of $46.6 million for the quarter, compared to a loss of $32.3 million in the prior year, and a net loss of $96.1 million for the six months, down from $173.6 million in the same period last year.

The increase in revenue was primarily driven by sales of IMCIVREE, the company's lead product, which is approved for treating obesity due to specific genetic deficiencies. The U.S. market accounted for approximately 66% of product revenue, while international sales contributed 34%. The company has achieved market access for IMCIVREE in over 20 countries outside the U.S. and continues to pursue additional approvals. However, total costs and expenses rose to $93.8 million for the quarter, up 35% from the previous year, largely due to increased research and development costs and selling, general, and administrative expenses.

In terms of strategic developments, Rhythm Pharmaceuticals has made significant investments in its research and development pipeline, particularly in expanding its MC4R pathway program. The company is advancing multiple clinical trials, including a pivotal Phase 3 trial for setmelanotide in acquired hypothalamic obesity, which recently reported positive topline results. Additionally, the company is exploring new formulations and delivery methods for its products, including a weekly administration option for setmelanotide, although development of this formulation has been paused in favor of advancing RM-718, another investigational MC4R agonist.

As of June 30, 2025, Rhythm Pharmaceuticals had approximately $291 million in cash and cash equivalents, bolstered by a recent public offering that raised approximately $189.2 million in net proceeds. The company anticipates that its existing cash resources, combined with the proceeds from this offering, will be sufficient to fund operations for at least the next 24 months. However, the company continues to face challenges related to its accumulated deficit of $1.3 billion and ongoing operating losses, which it expects to continue for the foreseeable future as it invests heavily in clinical development and commercialization efforts.

Looking ahead, Rhythm Pharmaceuticals plans to submit applications for regulatory approval of setmelanotide for additional indications and continue its efforts to expand its market presence. The company remains focused on building its commercial infrastructure and enhancing its sales and marketing capabilities to support the growth of IMCIVREE and its future product candidates. However, the company acknowledges the inherent risks and uncertainties in the biopharmaceutical industry, including regulatory challenges, competition, and the need for ongoing funding to support its operations and development programs.